MAPT and amyloidosis: Efforts are underway to develop PET tracers for other protein aggregates mentioned above, although these are challenged by the generally lower density of the pathological deposits (hence, binding sites)—requiring high-affinity tracers—and the possibility of co-occurrence of co-pathologies (such as amyloid or tau) that may occur, e.g., due to age—requiring high tracer selectivity.